You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers from Memorial Sloan Kettering found that many cancer patients harbor germline variants, sometimes in unexpected genes, that could inform their care.
The initial phase of GENIE, which stands for Genomics, Evidence, Neoplasia, Information, Exchange, involves seven founding members and two informatics partners.
MSK will collect the samples and Illumina will analyze them for ctDNA using its sequencing technology.
A team led by Memorial Sloan Kettering researchers showed advantages of the basket trial design in identifying precision treatment leads for rare cancer populations.
So far, results from the MSK-IMPACT test have been reported for more than 4,500 patients.
Teams tracked immune cell infiltration, PD-L1 expression, and more in tumors from BRCA1/2-mutated ovarian cancers or mutation-rich endometrial cancer subtypes.
The Broad will partner with Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center on a large tumor sequencing study.
The results offer hints at future applications of the platform for use in pharmaceutical partnerships and for clinical diagnostics.
Despite the findings of the Hopkins study, for practical and economic reasons many diagnostic laboratories currently only sequence tumor samples or do not believe the tumor-normal approach is necessary.
Memorial Sloan Kettering Cancer Center's John Chodera wants to build better computational models to guide drug discovery.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.